Centralized IRB System Could Speed Product Development, Merck Tells CBER
Executive Summary
A centralized institutional review board process could speed product development and reduce unnecessary paperwork, Merck regulatory affairs official Mark Bagarazzi said
You may also be interested in...
Adverse Event Reporting Harmonization Is Goal Of Joint FDA/NIH Task Force
An HHS task force is preparing to release a guidance on harmonizing the federal government's clinical adverse event reporting policies
Adverse Event Reporting Harmonization Is Goal Of Joint FDA/NIH Task Force
An HHS task force is preparing to release a guidance on harmonizing the federal government's clinical adverse event reporting policies
CBER Embarks On “Critical Path”: Pre-Pre-IND Meeting Guidance Requested
FDA will consider defining the procedures for requesting "pre-pre-IND" meetings, the agency said at a public workshop on facilitating biologics development Oct. 7